Abstract
Malignant ascites in patients with gynecological malignancies is associated with poor prognosis and poor quality of life. The bispecific trifunctional antibody removab ® (anti-EpCAM x anti-CD3) belongs to a new class of intact antibodies that has been developed for targeted therapy of epithelial tumors. The two binding sites of removab ® are directed against epithelial tumor cells (EpCAM +) and T-cells (CD3 +) thus recruiting T-cells in the direct environment of tumor cells. Simultaneously, mediated by the intact Fc-fragment removab ® binds to FcγI/IIIR + accessory cells (e.g. macrophages, natural killer cells, dendritic cells) that are mandatory for the induction of a tumor-specific immune response.